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Abstract
Background: Using a recently described monolayer assay amenable to high throughput screening
format for the identification of potential Nipah virus and Hendra virus antivirals, we have partially
screened a low molecular weight compound library (>8,000 compounds) directly against live virus
infection and identified twenty eight promising lead molecules. Initial single blind screens were
conducted with 10 μM compound in triplicate with a minimum efficacy of 90% required for lead
selection. Lead compounds were then further characterised to determine the median efficacy
(IC50), cytotoxicity (CC50) and the in vitro therapeutic index in live virus and pseudotype assay
formats.
Results: While a number of leads were identified, the current work describes three commercially
available compounds: brilliant green, gentian violet and gliotoxin, identified as having potent antiviral
activity against Nipah and Hendra virus. Similar efficacy was observed against pseudotyped Nipah
and Hendra virus, vesicular stomatitis virus and human parainfluenza virus type 3 while only
gliotoxin inhibited an influenza A virus suggesting a non-specific, broad spectrum activity for this
compound.
Conclusion: All three of these compounds have been used previously for various aspects of anti-
bacterial and anti-fungal therapy and the current results suggest that while unsuitable for internal
administration, they may be amenable to topical antiviral applications, or as disinfectants and
provide excellent positive controls for future studies.
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Background
Nipah (NiV) and Hendra (HeV) viruses are two newly
emerging zoonotic paramyxoviruses that are lethal to
humans. HeV was first isolated during two outbreaks of
respiratory illness in horses in Australia [1]. Highly lethal
in horses, these initial HeV outbreaks also resulted in two
human fatalities, including one person initially present-
ing with a flu-like illness followed by apparent recovery
who subsequently died one year later due to meningoen-
cephalitis [2]. HeV has continued to re-emerge in eastern
Australia with more than twelve separate outbreaks being
documented [3] resulting in over 30 equine deaths and an
additional human fatality in each of August 2008 [4] and
August 2009 [5]. The initial NiV outbreak occurred in
peninsular Malaysia in 1998 and by June 1999, more than
265 cases of encephalitis, including 105 deaths, had been
reported in Malaysia and 11 cases of disease with one
death in Singapore [6]. In addition to the human health
impact, the economic impact of this disease was dramatic.
Containment procedures resulted in the slaughter of
almost 1.2 million pigs and the virtual closure of the pig
farming industry in Malaysia. Electron microscopy, sero-
logic, and genetic studies indicated that this virus was a
paramyxovirus, subsequently named NiV after the village
in Malaysia from which one of the first isolates was
obtained from the cerebrospinal fluid of a fatal human
case [6,7]. Serological surveillance and virus isolation
studies indicated that NiV resides naturally in flying foxes
in the genus Pteropus (reviewed in [8]). NiV has contin-
ued to re-emerge in Bangladesh causing fatal encephalitis
in humans and for the first time, person-to-person trans-
mission appeared to have been a primary mode of spread
[9-14]. In addition, there appeared to be direct transmis-
sion of the virus from it's natural host, the flying fox, to
humans, and the case mortality rate was ~70%; signifi-
cantly higher than any other NiV outbreak to date.
A number of recent reports of potential vaccine
approaches [15-19] and experimental therapeutics [19-
25] have been described, however, there is still no vaccine
or antiviral treatment specifically indicated for either HeV
or NiV infections (reviewed in [26]). An open-label trial of
ribavirin in 140 patients during the initial NiV outbreak in
Malaysia showed ribavirin therapy was able to reduce
mortality of acute NiV encephalitis [27]. While this study
reported no serious side effects, ribavirin has been associ-
ated with a range of side effects primarily related to
haemolytic anaemia [28]. The antiviral efficacy of ribavi-
rin has also been demonstrated against HeV and NiV in
vitro [29,30]. In vivo, a recent study showed that the inter-
feron inducer poly(I)-poly(C12U), but not ribavirin, was
able to prevent mortality in five of six animals in a ham-
ster model of NiV infection [31]. Recently, we described
the antiviral properties of chloroquine against Henipavi-
ruses in vitro [32], although a recent study reported no anti
Henipavirus effects in a ferret model in vivo [33].
There have also been a number of recent reports describ-
ing the development of surrogate assays to screen and
evaluate HeV and NiV antivirals or perform serological
surveys at biosafety level 2 (BSL2) [24,25,34-37]. These
pseudotyped assays provide excellent surrogate BSL2
assays for the evaluation of virus entry and fusion mecha-
nisms, enabling wider access for potential antiviral evalu-
ation. Significantly, our recent description of chloroquine
as an effective henipavirus antiviral was identified using a
modified, multicycle pseudotype screening assay with
efficacy subsequently confirmed against live virus [32].
This study demonstrates that surrogate assays can provide
legitimate antiviral leads, however, these will ultimately
require live virus confirmation. Mini-genome assays
[23,38] may provide an effective complimentary
approach to pseudotyped assays but ultimately, inhibitors
identified using these approaches must also be validated
against live virus at biosafety level 4 (BSL4). In an effort to
expedite the process of antiviral development, we have
recently described an immunoassay format amenable to
high throughput screening (HTS) of antiviral compounds,
directly against live HeV and NiV [30]. Using this live virus
HTS approach, we have identified a number of potential
antiviral compounds [39], three of which are commer-
cially available, public access molecules. While these com-
pounds may only have limited potential therapeutic uses,
they provide an excellent group of positive controls with
which to evaluate and standardise subsequent screening
assays. To this end, in an effort to further validate surro-
gate assays for antiviral screening approaches, we have
compared the efficacy of these compounds using our
recently described multicycle replication pseudotype
assay [32].
Results
Utilising a simple monolayer based assay amenable to
HTS of antivirals directly against live virus [30], we per-
formed a preliminary single blind screen of a library of
8,040 low molecular weight molecules. This assay incor-
porates immunological detection of the viral nucleopro-
tein (N) following infection and fixation of cell
monolayers. We have previously demonstrated a linear
relationship between N protein expression and viral inoc-
ulum [30], and for clarity, we have also directly compared
the titer of infectious virus recovered from Vero cells with
the level of N protein expression detected using this
immunoassay approach (Figure 1). While the immu-
noassay is largely insensitive to changes in viral inoculum
below 100 TCID50, there is a linear relationship between
viral inoculum and protein expression for both HeV and
NiV above 100 TCID50 comparable to that observed for
viral RNA and infectious virus titers recovered from theVirology Journal 2009, 6:187 http://www.virologyj.com/content/6/1/187
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same wells (Figure 1). Our initial screen was conducted
using 1,000 TCID50  of each virus ensuring N protein
expression was well within the linear portion of this curve
and would be proportional to the levels of infectious virus
recovered. This initial screen resulted in a predictable dis-
tribution of inhibition values with the majority of com-
pounds exhibiting between 25 and 75% inhibition of NiV
infection [38]. The primary screen of DMSO stocks
revealed 54 compounds inhibiting NiV infection by
greater than 90%. To confirm inhibitory activity 49 com-
pounds were sourced from lyophilised stocks and redis-
solved in DMSO to be retested as fresh stocks. On retest,
28 of the compounds exhibited greater than 90% inhibi-
tion of NiV in vitro. Dose-response experiments were per-
formed on each of these 28 compounds to determine the
IC50 concentrations for each in addition to the CC50 deter-
mined in Vero cells (Figure 2). Upon unblinding, three of
these remaining 28 lead compounds were identified as
brilliant green, gentian violet and gliotoxin (Figure 3),
commercially available compounds with a variety of his-
torical applications. All three compounds were at the
lower end of the range of IC50 values determined, but were
also at the lower end of the CC50 range, indicating higher
toxicity than many of the novel compounds identified
(Figure 2).
All three compounds were shown to effectively inhibit
both NiV and HeV (Table 1) infection. NiV IC50 values
for brilliant green and gliotoxin were ten fold lower than
ribavirin while gentian violet was four fold lower than rib-
avirin (Table 1). HeV IC50 values for brilliant green and
gliotoxin were three fold lower than ribavirin while gen-
tian violet was slightly less effective than ribavirin (Table
1). Incubation of compounds in parallel with virus inhi-
bition assays reveals all three compounds are cytotoxic at
high concentrations using both ATP based and resorufin
based measures of cytotoxicity (Table 1). The concentra-
tion of compound exhibiting 50% cytotoxicity (CC50) for
all three compounds was similar in Vero cells but varied
more than three-fold in 293T cells reflecting the lack of
correlation often observed between measures of cytotoxic-
ity. Of note, all three compounds were considerably more
cytotoxic than ribavirin in Vero cells. The therapeutic
index (TI) for each compound indicates all three com-
pounds are more amenable to inhibition of NiV than HeV
(Table 1) but all have very narrow margins of safety. Con-
firmation of henipavirus inhibition was achieved with a
recently described NiV-G-VSV-pseudotype assay which
mimics multicycle replication [32] and the related HeV-G-
VSV assay (Table 2). Additionally, antiviral efficacy was
evaluated against the parent pseudotyped virus (VSV),
HPIV3 and an influenza H1N1 virus (Table 2). The simi-
lar levels of inhibition observed for most of these viruses
would indicate the antiviral activity of these compounds
occurs by a process not specific to henipavirus entry. Of
note however, only gliotoxin exhibited a dose-dependant
inhibition of influenza virus (Table 2) suggesting brilliant
green and gentian violet efficacy is not simply a product of
viral envelope disruption. Both brilliant green and glio-
toxin exhibited similar IC50s for each of the pseudotyped
viruses, suggesting their action may be related to the VSV
backbone, rather than the specific glycoproteins for each
virus. Curiously, gentian violet displayed a striking selec-
tivity for pseudotyped HeV inhibition, and to a lesser
Detection of NiV (a) and HeV (b) via end-point titration, Taqman PCR and immunodetection Figure 1
Detection of NiV (a) and HeV (b) via end-point titration, Taqman PCR and immunodetection. 1/2 log dilutions of 
virus (100 μl) were incubated with 20,000 Vero cells per well for 24 h at 37°C and 5% CO2. Virus released into the media was 
quantified by end-point titration and TCID50/ml (n = 3) determined using the Reed-Meunch method [73]. Monolayers were 
either fixed with methanol, air dried and immunostained with anti-NiV-nucleoprotein polyclonal antisera as previously 
described [30] or viral RNA was extracted from cells (n = 3) and Taqman PCR was used to quantitative the relative expression 
of the N gene [17,23]. S/N, signal:noise ratios calculated as signal/background values (n = 15). Values are expressed as the mean 
+/- S.E.Virology Journal 2009, 6:187 http://www.virologyj.com/content/6/1/187
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extent, pseudotyped NiV (Table 2). This unexpected result
may potentially signal a more specific antiviral action
attributable to gentian violet, or alternatively, an
enhanced sensitivity of pseudotyped assay formats when
compared to live virus assays. This may have considerable
implications for the use of surrogate assay screens as the
primary tools for antiviral discovery. A more detailed fol-
low-up of this observation is currently underway.
Time of addition experiments indicated that preincuba-
tion of cells with either brilliant green or gentian violet
prior to NiV infection resulted in more effective inhibition
of viral protein expression than when compounds were
added during or after virus infection (Figures 4a and 4b).
This may be due in part to increased cytotoxicity associ-
ated with longer times of compound exposure to the cell
monolayer, however, gliotoxin which exhibits similar lev-
els of cytotoxicity, did not induce enhanced antiviral
activity under the same conditions (Figure 4c). Preincuba-
tion of brilliant green with virus prior to viral infection
also resulted in enhanced inhibition of viral protein
expression (Figure 4a), viral genome expression (Figure
5a) and release of infectious virus (Figure 5b) suggesting a
direct effect on viral particles. Gliotoxin and gentian violet
efficacy appeared independent of the time of addition
suggesting they may be exerting their effects subsequent to
virus binding and entry. Similar results were observed
with time of addition experiments during HeV infection
but are not shown for brevity.
As an indication of the effect of these compounds on the
cellular inflammatory response, an evaluation of the
induction of the cytokines IL-8 and TNF-α was also per-
formed. Real Time PCR revealed brilliant green (1 μM)
strongly induced both IL-8 and TNF-α expression fifteen
to twenty fold (Figure 6). In contrast, gliotoxin suppressed
TNF-α expression with mild (two fold) induction of IL-8
by both gentian violet and gliotoxin compared to DMSO
treated control cells (Figure 6).
Discussion
We have recently described a reliable and sensitive HTS
method that potentially allows the screening of large
libraries of compounds for antiviral drug discovery in vitro
[30]. Utilising this approach, we have screened over 8,000
low molecular weight compounds from a drug discovery
collection for their antiviral activity against NiV infection.
This method facilitated the rapid identification of twenty-
eight potential NiV antivirals including three commer-
cially available compounds with IC50  values in the
nanomolar range. To further validate surrogate assay
approaches, we have also confirmed efficacy using a
recently described NiV-G-VSV-pseudotype assay which
mimics multicycle replication [32].
Gentian violet (a.k.a. crystal violet) was introduced as an
antiseptic by Sterling in 1890 and is used at a concentra-
tion of 1-2% in aqueous solutions [40]. Gentian violet is
a cationic triphenylmethane dye which has been used in
medicine for its antibacterial, antifungal, and antiparasitic
activities (Reviewed in [41]) and has also been used as a
mycostatic agent in poultry feed [42]. Gentian violet
inhibits DNA replication in a number of bacteria [43] and
several hypotheses have been provided to explain the
selective toxicity of gentian violet in bacteria and trypano-
somes (reviewed in [41]) including alteration of the redox
potential by the dye, inhibition of protein synthesis, dis-
ruption of Ca2+ homeostasis and a photodynamic action
of gentian violet has been described in both bacteria and
Trypanosoma cruzi. Gentian violet has been shown to
HTS screening of a small compound library against live NiV Figure 2
HTS screening of a small compound library against 
live NiV. Cells were treated with 10 μM of each compound 
(100 μl) immediately prior to infection with 1,000 TCID50 
NiV in 100 μl. Cells were incubated overnight at 37°C. Mon-
olayers were fixed with methanol, air dried and immunos-
tained with anti-NiV-N polyclonal antisera as described 
above. (a) Dose response curves were generated for 28 
compounds with >90% inhibition (10 μM) showing a range of 
50% inhibitory concentration (IC50) values all less than 2 μM 
(n = 3). (b) A wide range of 50% cytotoxicity concentration 
(CC50) values was observed for these 28 compounds (n = 3). 
Values determined for brilliant green (BG), gentian violet 
(GV) and gliotoxin (glio) are indicated.Virology Journal 2009, 6:187 http://www.virologyj.com/content/6/1/187
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depress protein synthesis in fibroblasts in vitro [44] and
Hoffmann and co-workers [45] found that gentian violet
is a potent inhibitor of amino acid transport and that this
inhibition is apparently responsible for its inhibitory
effect on T. cruzi protein synthesis.
Recently, Nagayama [46] examined the antiviral activity
of gentian violet and gentian violet-dyed cloth against the
influenza A (H1N1) virus. When 106 TCID50 virus was
exposed to 0.0063% (~160 μM) gentian violet, the resid-
ual viable count decreased to below three logs within 30
min and below five logs at 60 min. This indicates that the
interaction of gentian violet with the influenza virus is
very rapid and gentian violet completely destroys the
infectivity of the influenza virus within 60 min. Electron
microscopy of gentian violet treated viral envelopes con-
firmed destruction by gentian violet. While we did not
observe clear inhibition of an H1N1 virus in the current
study, cellular toxicity prevented effective testing of con-
centrations greater than 100 μM. The interaction of cati-
onic dyes with cellular membranes has been established
for many years [47-50] and for this reason they have been
applied in the study of membrane function in mitochon-
dria or intact plasma membranes. Antiviral efficacy may
be due to cationic dyes binding directly to the membranes
causing perturbation of the membrane structure [51] as
lipid bilayers are solvents for apolar and amphipathic
compounds such as gentian violet [52,53].
Chemical structures of a Figure 3
Chemical structures of a. brilliant green, b. gentian violet and c. gliotoxin.
Table 1: IC50, CC50 and therapeutic index (TI) values calculated for each compound against live Nipah and Hendra viruses.
Brilliant Green Gentian Violet Gliotoxin Ribavirin
NiV IC50 (nM) 218 525 149 3,897
HeV IC50(nM) 778 2,679 579 2,241
CellTiter-Glo® CC50(nM) 4,672 5,865 4,896 149,745
alamarBlue® CC50(nM) 861 2,828 1,609 NDa
NiV TI (CellTiter-Glo®) 21.39 11.16 32.81 38.42
NiV TI (alamarBlue®) 3.95 5.39 10.80 NDa
HeV TI (CellTiter-Glo®) 6.00 2.19 8.44 66.82
HeV TI (alamarBlue®) 1.11 1.06 2.78 NDa
a ND = not determined, values are averages of at least 3 independent experiments.Virology Journal 2009, 6:187 http://www.virologyj.com/content/6/1/187
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Previous studies suggest the potentiation of the antiviral
effects of gentian violet (and the related brilliant green)
when applied following NiV infection could be attributa-
ble to either a direct interaction with viral and/or cellular
membranes or via a general decrease in protein synthesis.
Gentian violet did induce an immediate increase in intra-
cellular calcium concentrations and a large decrease in
sodium levels suggesting the integrity of cellular mem-
branes may have been compromised (data not shown)
but did not induce significant changes in either IL-8 or
TNF-α expression. Preincubation of cells with gentian vio-
let prior to virus infection does reduce the expression of
viral protein (and by inference, a proportional decrease in
viral replication) but does not appear to differentially
effect viral replication when preincubated with virus, or
when applied during or immediately after virus infection.
It is likely that any effect due to direct interaction with cel-
lular membranes should be comparable both during and
post-infection with the caveat that post-infection provides
a greater time span for this interaction to occur.
Brilliant green (a.k.a. malachite green) has also been used
as an antiseptic, similar to gentian violet. The value of cer-
tain triphenylmethane dyes such as brilliant green and
gentian violet as selective agents for isolation of typhoid
bacteria was first reported by Drigalski and Conradi
(Reviewed in [54]). These dyes have since been used
extensively as aids in the isolation of bacteria of the
typhoid and paratyphoid groups (Salmonella). Brilliant
green inhibits the growth of bacteria at lower concentra-
tions than most other dyes and is by far the most widely
used dye in selective media (reviewed in [54]). Bakker and
colleagues [55] demonstrated inhibitory activity against
streptococcus, proteus and staphylococcus spp. in addi-
tion to candida albicans. Brilliant green has been used
widely as an anti-fungal agent in fish hatcheries [56-58]
Table 2: IC50 values calculated for pseudotyped Nipah (pNiV), Hendra (pHeV), VSV (pVSV), HPIV3 and Influenza viruses.
Brilliant Green Gentian Violet Gliotoxin
pNiV IC50 (nM) 42 61 100
pHeV IC50 (nM) 34 0.3 366
pVSV IC50 (nM) 15 268 232
HPIV3 IC50(nM) 248 860 527
Influenza IC50(nM) DNCa DNCa 13,786
a DNC = non-linear regression curve did not converge, values are averages of at least 3 independent experiments.
Effect of time of addition of compounds on NiV antiviral activity for brilliant green (a) gentian violet (b) and gliotoxin (c) Figure 4
Effect of time of addition of compounds on NiV antiviral activity for brilliant green (a) gentian violet (b) and 
gliotoxin (c). Inhibition of NiV infection as measured by viral nucleoprotein expression determined by immunoassay. For cell 
pre-incubation (Cells), each compound was incubated with cells for 60 min, media was then removed and virus inoculum 
(1,000 TCID50/ml NiV) added and incubated for 60 min, then inoculum was removed and replaced with EMEM-10 and cells 
were incubated overnight. For Pre-infection (Pre), virus was incubated with compound for 60 min, then added to cells for 60 
min prior to replacement with EMEM-10 overnight. Co-infection (Co) wells received compound and virus inoculum simultane-
ously, incubated for 60 min, then media was replaced with EMEM-10 and cells were incubated overnight. Post-infection (Post) 
wells were infected with virus for 60 min followed by inoculum removal and replacement with compound in media. Cells were 
incubated and assayed as above. Values are expressed as the Mean +/- S.E (n = 3).Virology Journal 2009, 6:187 http://www.virologyj.com/content/6/1/187
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(Reviewed in [58]) but in recent years the use of brilliant
green in aquaculture has been banned in several countries
due to accumulating evidence of genotoxic and carcino-
genic effects [59-62]. However, a recent study by Bahna
and co-workers [63] evaluated a combination of low con-
centrations of both brilliant green and chlorhexidine in
vitro as an alternative to alcohol based mouthwashes for
preventing oral cavity infections in immunocompromised
and cancer patients suggesting opportunities may still
exist for brilliant green based therapeutics.
The enhanced efficacy of brilliant green when preincu-
bated with cells and/or virus would suggest potential
intercalation into, and disruption of both cellular and
viral membranes as potential modes of action. We
observed a rapid and sustained increase in intracellular
calcium and sodium concentrations with an associated
decrease in pH (data not shown) also supporting this pos-
sibility. Additionally, brilliant green induced a 15-20 fold
increase in TNF-α and IL-8 expression, respectively, sug-
gesting the stimulation of a considerable inflammatory
response. The similar efficacy seen with a NiV-G pseudo-
typed virus, the parent VSV, and HPIV3 indicates brilliant
green's antiviral activity is likely not specific to henipavi-
rus entry although we did not observe antiviral efficacy
against an influenza virus.
Gliotoxin activity against various bacteria and fungi has
been known for some time (Reviewed in [64]) and the
first report of antiviral activity was made by Rightsel and
co-workers [65] describing activity against poliovirus type
2, herpes simplex virus and against influenza A virus, the
latter confirmed in the current study. Further studies
reported the antiviral activity of gliotoxin against numer-
ous viruses including poliovirus types 1, 2 and 3, rhinovi-
rus strain HGP, ECHO virus types 12 and 28, measles
virus, coxsackie virus, Sendai virus, influenza virus and
Newcastle disease virus [64,66]. Subsequent studies iden-
tified the antiviral action against poliovirus as being due
to the inhibition of viral RNA replication [67], specifically
via actions on the poliovirus polymerase 3Dpol [68]. The
observation in the current study that gliotoxin exerts its
effects independently of addition prior to or immediately
following virus infection, suggests an action subsequent
to viral binding and entry, such as replication, confirmed
by our pseudotype data. Consistent with the reported
Effect of time of addition of compounds on NiV genome replication and infectious titer Figure 5
Effect of time of addition of compounds on NiV genome replication and infectious titer. (a) Relative N gene 
detection (Ct vs. treatment) determined by Taqman PCR for brilliant green (BG), gentian violet (GV) and gliotoxin (glio). Infec-
tious NiV titers determined by end point titration in the supernatants of Vero cells treated with brilliant green (b) gentian vio-
let (c) and gliotoxin (d) before, during and after virus infection overnight. Values are expressed as the Mean +/- S.E (n = 3).Virology Journal 2009, 6:187 http://www.virologyj.com/content/6/1/187
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immunosuppressive actions of gliotoxin, we observed a
decrease in TNF-α expression in Vero cells following glio-
toxin treatment. Pre-incubation of compound with cells
prior to virus infection may enable efficacious levels of gli-
otoxin to enter and remain inside the cell, reducing any
potential differences expected between pre-infection and
post-infection treatment. Efficacy seen with pre-treatment
of virus prior to infection of cell monolayers may indicate
a direct interaction with one or more viral proteins such as
the viral polymerase. Traditionally, the usefulness of glio-
toxin and related fungal metabolites has been limited by
their toxicity. However, studies highlighting the potential
of gliotoxin as an anticancer agent [69,70] may provide
important research into the development and evaluation
of less toxic analogues of gliotoxin.
Conclusion
In the current study we have screened over 8,000 small
molecules for antiviral activity and demonstrated potent
antiviral activity of three commercially available com-
pounds against NiV and HeV, recently emerged BSL4
pathogens for which no vaccine or therapeutic indications
exist. Despite the known toxicity associated with these
compounds, gentian violet has been, and still is, used
extensively for a range of topical applications. In our quest
to discover novel antiviral agents that may be amenable to
oral or parenteral administration in the event of acute
viral exposure, the three compounds described here may
prove excessively toxic for systemic use. However, their
use in topical applications for inactivation of viruses in
field situations or in hospital settings may warrant further
investigation. Additionally, gliotoxin, given its identified
actions as a viral polymerase inhibitor, may also provide
an important parent molecule with which to develop sec-
ond generation, non-toxic polymerase inhibitors. This
proof-of-concept study demonstrates the utility of a live
virus HTS approach for identifying potential antiviral
compounds. While all novel drug development is a costly
and time-consuming process, eliminating additional live
virus confirmation steps required to validate leads identi-
fied by surrogate assay screening programs will clearly
reduce both the development time and the number of
false positives generated. However, the considerable cost
and biosecurity advantages of surrogate screening
approaches will ensure they have a place in antiviral dis-
covery efforts. As evidence of the comparable results
obtained through pseudotyped virus screening, our col-
laborative group recently identified chloroquine as an
effective inhibitor of HeV and NiV in vitro [32] in a pri-
mary pseudotype screen, followed by live virus confirma-
tion. In the current study, to further validate this
approach, we have confirmed compound efficacy against
live virus infection with that observed using a novel VSV
pseudotype assay mimicking multicycle replication.
While the three compounds reported in this study may
only be useful for topical administration, or as disinfect-
ants, this screening approach has also identified a number
of promising novel candidate antivirals [38] to be evalu-




African Green Monkey Kidney (Vero) cells were grown in
Minimal Essential Medium containing Earle's salts
(EMEM), antibiotics (100 U Penicillin, 100 μg/ml Strep-
tomycin and 500 μg/ml Fungizone) and 10% foetal calf
serum (FCS), designated EMEM-10. 293T (human kidney
epithelial) cells were grown in Dulbecco's modified
Eagle's medium (DMEM; Mediatech-Cellgro) supple-
mented with 10% fetal bovine serum and antibiotics at
37°C in 5% CO2. All transfections and pseudotype infec-
tion experiments were performed in OptiMEM (Invitro-
gen) supplemented with antibiotics. NiV was isolated in
Vero cells from the brain of a human fatally infected in the
1998-99 Malaysian outbreak and was passaged three
times in Vero cells then double plaque purified and pas-
saged a further three times in Vero cells as previously
described [71]. HeV was isolated in Vero cells from the
lung of a horse infected in the Brisbane outbreak in Octo-
ber 1994 and was passaged five times in Vero cells fol-
lowed by triple plaque purification and a further five
passages in Vero cells as previously described [72]. HeV
and NiV stock titer were adjusted to 1 × 106 TCID50/ml.
For titrations, serial ten-fold dilutions of samples were
made in EMEM and 25 μl transferred to five wells of a 96-
Expression of IL-8 and TNF-α following treatment with bril- liant green, gentian violet or gliotoxin Figure 6
Expression of IL-8 and TNF-α following treatment 
with brilliant green, gentian violet or gliotoxin. Vero 
cell monolayers in 48 well plates were treated with 1 μM 
compound overnight followed by RNA extraction, DNAse 
treatment, reverse transcription and real time PCR assay 
using SYBR green. Gene expression was normalised using 
GAPDH expression and is expressed as a fold change relative 
to untreated wells (Mean ± S.E.M.).Virology Journal 2009, 6:187 http://www.virologyj.com/content/6/1/187
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well microtitre plate. Vero E6 cells in EMEM containing
10% foetal calf serum were added (2 × 104 cells/well).
Plates were incubated at 37°C for 5-7 days and wells dis-
playing cytopathic effect were scored as infected. Virus
titre was calculated using the Reed-Meunch method [73]
and the limit of detection was 126 TCID50/ml virus. All
work with live virus was carried out under Biosafety Level
4 (BSL-4) conditions.
Titers of human parainfluenza virus type 3 (HPIV3) virus
stocks was assessed by plaque assay performed as
described previously [74] while the titer of influenza A/
swine/Rachaburi/2000 (H1N1) was determined by end
point titration in Vero cells.
Nipah virus infection of cells and library screening
Vero cells were seeded at a density of (2 × 104) into indi-
vidual wells of 96-well microtitre plates and incubated at
37°C overnight in 100 μl EMEM-10. Prior to NiV inocula-
tion, media was discarded and 100 μl of 20 μM of differ-
ent test compounds were added to each well in triplicate.
Under BSL4 conditions, 1,000 TCID50 of virus in EMEM-
10 were added to each well of Vero cells in volumes of 100
μl diluting the final test compound concentrations to 10
μM. After an overnight incubation at 37°C, the culture
medium was then discarded, plates were immersed in ice-
cold absolute methanol, enclosed in heat sealed plastic
bags and the bags surface sterilized with Lysol during
removal from the BSL4 laboratory. Methanol-fixed plates
were air dried at room temperature for a minimum of 30
min prior to immunolabeling.
HTS Immunolabeling assay
Assays were performed as previously described [30].
Briefly, plates were washed 3 times with Phosphate Buff-
ered Saline containing 0.05% Tween-20 (PBS-T). Plates
were then protein blocked with 100 μl of 2% skim milk in
PBS-T and incubated at 37°C for 30 min. After protein
blocking, plates were washed 3 times with PBS-T, fol-
lowed by incubation with 100 μl anti-NiV antibody (rab-
bit polyclonal anti-N [75] complements of Brian Shiell)
diluted 1:1,000 in PBS-T containing 2% skim milk for 30
min at 37°C and then washed 3 times with PBS-T. Plates
were incubated with 1% H2O2 (Sigma) for 15 min at
room temperature then washed with PBS-T 3 times.
100  μl of anti-rabbit conjugated HRP (Sigma) diluted
1:2,000 in PBS-T containing 2% skim milk, were added to
each well and plates incubated at 37°C for 30 min then
washed 3 times with PBS-T. For detection, 100 μl of
Chemiluminescent Peroxidase Substrate-3 (CPS-3,
Sigma) diluted 1:10 in Chemiluminescent assay buffer
(20 mM Tris-HCl, 1 mM MgCl2, pH = 9.6) were added to
all wells. Plates were incubated at room temperature for
approximately 15 min, and then read using a Luminoskan
Ascent luminometer (Thermo Fisher Scientific, Waltham,
USA) using 100 mSec integration per well.
Antiviral lead identification and toxicity testing
Test compounds were initially screened in triplicate (10
μM) and those exhibiting 90% or greater reduction in NiV
infection (compared to untreated control wells) were des-
ignated as antiviral leads. Following the initial screening
and identification of leads, the selected compounds were
further characterised to determine their IC50 against both
NiV and HeV in vitro, in addition to their 50% cytotoxicity
(CC50) concentrations. For antiviral assays, half-log dilu-
tions (20 μM-63 nM) of each lead compound were
assayed against NiV and HeV as described above. Meas-
urements were collated and non-linear regression analysis
performed using GraphPad Prism software (GraphPad
Software, San Diego, CA, USA) to determine the IC50.
Compound cytotoxicity was determined using both the
CellTiter-Glo® cytotoxicity kit (Promega, Madison, USA)
in Vero cells and alamarBlue® dye (Invitrogen, Carlsbad,
CA, USA) in 293T cells, as per the manufacturer's instruc-
tions. Vero cell cytotoxicity was determined in monolay-
ers (40,000 cells) in 96 well plates incubated with half-log
dilutions of 200 μl each compound in EMEM-10 (20 μM-
63 nM, n = 3) overnight at 37°C. Media was removed and
100 μl of CellTiter-Glo® Reagent, diluted 1:5 with chemi-
luminescent assay buffer, was added to each well, mixed
well to lyse cells, equilibrated to room temperature for 10
min, and then read using a luminometer as described
above. 293T cell cytotoxicity assays were performed with
half-log dilutions of 80 μl each compound in OptiMEM
(4 μM-1 nM, n = 4) incubated overnight at 37°C with a
suspension of 10,000 cells in 384 well plates containing a
1:8 dilution of alamarBlue® dye. Fluorescence was then
read using a Perkin-Elmer EnVision multi-function plate
reader with an excitation filter of 535 nm and a 590 nm
emission filter. Non-linear regression analysis was per-
formed using GraphPad Prism software to determine the
CC50. To evaluate the margin of safety that exists between
the dose needed for antiviral effects and the dose that pro-
duces unwanted and possibly dangerous side effects (cyto-
toxicity), the therapeutic index for each lead compound
was then calculated from the efficacy and cytotoxicity data
(CC50/IC50).
Multicycle replication pseudotyped virus infection assays
The VSV-ΔG-RFP is a recombinant VSV derived from the
cDNA of VSV Indiana, in which the G gene is replaced
with the RFP gene. We obtained VSV-ΔG-RFP comple-
mented with VSV G from Michael Whitt (University of
Tennessee Health Science Center). Pseudotypes with NiV
F and G were generated as previously described for HeV
[34,76]. Briefly, 293T cells were transfected with either
VSV-G (gift from M. Whitt), HeV-G/F or NiV-G/F. 24 hrsVirology Journal 2009, 6:187 http://www.virologyj.com/content/6/1/187
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post-transfection, the dishes were washed and infected
(MOI of 1) with VSV-ΔG-RFP complemented with VSV G.
Supernatant fluid containing pseudotyped virus (HeV-G/
F, NiV-G/F or VSV-G) was collected 18 hrs post-infection
and stored at -80°C. For infection assays, HeV-G/F, NiV-
G/F or VSV-G pseudotypes were used to infect 293T cells
transfected with the corresponding G and F plasmids in
addition to a VENUS-YFP construct in the absence of
serum as previously described [31]. Briefly, compounds
were added in a 5 μl volume into 384-well polystyrene
black/clear bottom plates in serial 2-fold dilutions. A 70
μl volume of 104 293T cells that had been transfected with
plasmids encoding NiV, HeV or VSV G and F, and also
with Venus-YFP was then dispensed using a Multidrop
Combi dispenser (Thermo Labsystems), followed by
addition of 5 μl of pseudotyped virus. Plates were incu-
bated at 37°C for 48 hr and then read for two channel flu-
orescence intensity in a Perkin-Elmer EnVision multi-
function plate reader. For detecting RFP expression levels,
the wells were read from the top with a 535 nm (40 nm
bandpass) excitation filter and a 579 nm (25 nm band-
pass) emission filter. For detection of YFP expression, the
wells were read from the bottom with a 510 nm (10 nm
bandpass) excitation filter and 535 nm (25 nm bandpass)
emission filter. Additionally, to ensure the assays were not
contaminated with bacteria, an additional read of absorb-
ance at 590 nm was performed. Measurements were col-
lated and non-linear regression analysis performed using
GraphPad Prism software (GraphPad) to determine the
IC50 (RFP) or the CC50 (YFP).
Human parainfluenza virus type 3 (HPIV3) assays
A 5 μl volume of compounds were added into 384-well
polystyrene black/clear bottom plates in serial 2-fold dilu-
tions. A 70 μl volume of 104 293T cells were dispensed as
above, followed by the addition of 5 μl of HPIV3 (m.o.i.
= 0.8). Plates were incubated for 24 hr followed by immu-
nodetection of viral antigen using a cell monolayer ELISA
based assay. Briefly, 10 μl of 37% formalin was added to
wells for 10 min (final concentration ~4%). Cells were
then washed 3× with PBS, blocked with 80 μl 0.5% BSA
and 0.1% sodium azide in PBS for 30 min, washed again
and incubated for 60 min with 20 μl anti-HPIV3 serum
(Matteo Porotto, diluted 1:200 in PBS). Cells were washed
again, incubated with 20 μl protein-G-HRP conjugate
(Pierce, Rockford, IL.) for 30 min, then background per-
oxidase activity was quenched with two 20 min incuba-
tions with chemiluminescent substrate (CPS-3, Sigma
diluted 1:30 in PBS) followed by visualisation with the
same substrate diluted 1:5 in PBS. Luminescence was read
using the same multi-function plate reader as the previous
assay. Measurements were collated and non-linear regres-
sion analysis performed using GraphPad Prism software
(GraphPad) to determine the IC50.
Influenza assays
Compounds were serially diluted in EMEM-10 and 25 μl
was added to white 96 well plates containing 4 × 104 Vero
cells followed by 25 μl of Influenza A/swine/Rachaburi/
2000 (H1N1). Plates were incubated for 24 hrs followed
by detection of neuraminidase (NA) activity as a surrogate
for viral infection using the NA-Star® luminescent detec-
tion kit (Applied Biosystems). Briefly, 10 μl of media from
each well was added to 40 μl NA-Star® assay buffer, incu-
bated with 10 μl of NA-Star® substrate for 30 min at room
temperature, followed by addition of 60 μl of Accelerator
solution and luminescence was read immediately. To
determine the direct effect of compounds on NA activity,
25 μl of compound and 25 μl of virus were incubated for
30 min at 37°C, followed by addition of 10 μl of NA-Star®
substrate for 30 min at room temperature, addition of 60
μl of Accelerator solution and luminescence read as
above.
Viral RNA isolation and Taqman PCR
After overnight virus infection viral media was removed
from cells and 150 μl cell lysis buffer (RLT, Qiagen, con-
taining 0.1% β-mercaptoethanol) was added directly to
wells in 96 well plates. The cell lysate was aspirated into
PCR tubes and removed from the BSL4 laboratory. RNA
was extracted using the Qiagen RNeasy Mini kit as per the
manufacturer's instructions. RNA was eluted in a final vol-
ume of 50 μl RNase free water. Samples were stored at -
20°C prior to Taqman PCR analyses.
The specific NiV Taqman primers, probes and reaction
conditions were used as previously reported [17,23]. All
Taqman PCR oligonucleotide primer and probe
sequences used in this study are available on request.
Assays were performed in triplicate using a one-step pro-
tocol consisting of an initial reverse transcription reaction
followed immediately by cDNA amplification. All Taq-
man reagents were purchased from Applied Biosystems
except the primers, which were obtained from
Geneworks. RNA (2 μl) was added to 23 μl of PCR mix in
each well of a MicroAmp optical reaction plate containing
12.5 μl of Taqman One-Step PCR Mastermix, 0.625 μl of
40× Multiscribe/RNase inhibitor, 5.75 μl of distilled
water, 1.25 μl each of 18 μM NiV or HeV forward and
reverse primers, 1.25 μl of 5 μM HeV or NiV FAM-labeled
probe, 0.125 μl each of 10 μM 18SrRNAF and 18SrRNAR,
and 0.125 μl of 40 μM 18SrRNA-VIC-labeled probe. The
samples were amplified in a GeneAmp 7500 sequence
detection system (Applied Biosystems) using the follow-
ing program: 48°C for 30 min, 1 cycle; 95°C for 10 min,
1 cycle; and 95°C for 15 s and 60°C for 60 s, 45 cycles. To
correct for sample variation, CT values for viral genome in
samples were normalized against 18S rRNA expression
and expressed as normalised CT values.Virology Journal 2009, 6:187 http://www.virologyj.com/content/6/1/187
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Cytokine analysis
Briefly, vero cell monolayers in 48 well microplates (in
triplicate) were treated with either brilliant green, gentian
violet or gliotoxin (1 μM) or DMSO control (10 μM). Fol-
lowing overnight incubation RNA was extracted with the
Qiagen RNeasy kit according to the manufacturers instruc-
tions in a final volume of 40 μl. Eight μl of RNA from each
extraction was then digested with 1 unit of DNAse (Invit-
rogen) for 15 minutes at room temperature and subse-
quently inactivated for 10 minutes at 65°C according to
manufacturer's instructions. The RNA was then reverse
transcribed using the Superscript II (Invitrogen) kit. The
cDNA samples were diluted 1:5 and were assayed in trip-
licate for each gene of interest (TNF-α and IL-8) with a
SYBR green real time PCR kit (Sigma) using a total reac-
tion volume of 25 μl An ABI Prism 7900HT cycler was
used with the following cycling conditions: 95°C for 10
min, 1 cycle, 95°C for 15 s and 60°C for 60 s, 40 cycles.
GAPDH levels were measured in duplicate for each cDNA
sample to normalize CT values for subsequent comparison
and calculation of fold change in gene expression over
untreated cells. Primers for TNF-α and IL-8 were obtained
from SABiosciences.
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